- Home
- TARA
TARA
Protara Therapeutics Inc.
as 04-18-2025 1:43pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $20.00 | AVG Volume (30 days): | 298.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $10.48 | Next Earning Date: | 05-01-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Protara Therapeutics Inc. News
TARA Breaking Stock News: Dive into TARA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
GlobeNewswire
9 days ago
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
GlobeNewswire
a month ago
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Simply Wall St.
a month ago
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
a month ago
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
2 months ago
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
2 months ago
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire
3 months ago
Protara Highlights Recent Updates and Anticipated 2025 Milestones
Compare TARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARA Protara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.